XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Goodwill and Other Intangibles | 3 Months Ended
--- | ---
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangibles | Note 5 – Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the three months ended March 31, 2024 was as follows:
|  | Automotive |  |  | Medical |  |  | Total |
Balance as of December 31, 2023 |  | $ | 76,696 |  |  | $ | 27,377 |  |  | $ | 104,073 |
Currency translation and other |  |  | (1,543 | ) |  |  | (336 | ) |  |  | (1,879 | )
Balance as of March 31, 2024 |  | $ | 75,153 |  |  | $ | 27,041 |  |  | $ | 102,194 |
The Company’s cumulative goodwill impairment expense since inception was $19,509 as of March 31, 2024 and December 31, 2023, which includes Gentherm’s goodwill impairment of the Medical reporting unit in 2023. Other Intangible Assets Other intangible assets and accumulated amortization balances as of March 31, 2024 and December 31, 2023 were as follows:
|  | March 31, 2024 |  |  | December 31, 2023 |
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Accumulated Impairment |  |  | Net Carrying Value |  |  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Definite-lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 112,931 |  |  | $ | (72,958 | ) |  | $ | — |  |  | $ | 39,973 |  |  | $ | 115,465 |  |  | $ | (73,737 | ) |  | $ | 41,728 |
Technology |  |  | 44,871 |  |  |  | (29,268 | ) |  |  | — |  |  |  | 15,603 |  |  |  | 45,861 |  |  |  | (29,317 | ) |  |  | 16,544 |
Product development costs |  |  | 18,868 |  |  |  | (18,705 | ) |  |  | — |  |  |  | 163 |  |  |  | 19,434 |  |  |  | (19,270 | ) |  |  | 164 |
Software development |  |  | 1,007 |  |  |  | (50 | ) |  |  | — |  |  |  | 957 |  |  |  | 1,007 |  |  |  | — |  |  |  | 1,007 |
Indefinite-lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tradenames |  |  | 6,999 |  |  |  | — |  |  |  | (530 | ) |  |  | 6,469 |  |  |  | 7,039 |  |  |  | — |  |  |  | 7,039 |
Total |  | $ | 184,676 |  |  | $ | (120,981 | ) |  | $ | (530 | ) |  | $ | 63,165 |  |  | $ | 188,806 |  |  | $ | (122,324 | ) |  | $ | 66,482 |
In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore would require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. During the three months ended March 31, 2024, we recorded a non-cash impairment charge of $530 for one of our tradenames within the Medical segment. We are not presently aware of any other events or circumstances that would require us to revise the carrying value of our assets or liabilities as of March 31, 2024.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration